Sunshine Biopharma, Inc. (SBFM)
NASDAQ: SBFM · Real-Time Price · USD
1.500
+0.080 (5.63%)
At close: Aug 13, 2025, 4:00 PM
1.500
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:02 AM EDT
Sunshine Biopharma Revenue
Sunshine Biopharma had revenue of $9.41M in the quarter ending June 30, 2025, with 1.15% growth. This brings the company's revenue in the last twelve months to $36.34M, up 19.22% year-over-year. In the year 2024, Sunshine Biopharma had annual revenue of $34.87M with 44.75% growth.
Revenue (ttm)
$36.34M
Revenue Growth
+19.22%
P/S Ratio
0.10
Revenue / Employee
$698,880
Employees
52
Market Cap
6.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 34.87M | 10.78M | 44.75% |
| Dec 31, 2023 | 24.09M | 19.75M | 454.42% |
| Dec 31, 2022 | 4.35M | 4.12M | 1,802.41% |
| Dec 31, 2021 | 228.43K | 157.02K | 219.88% |
| Dec 31, 2020 | 71.41K | 50.29K | 238.10% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
SBFM News
- 6 weeks ago - Sunshine Biopharma Launches NIOPEG(R) Into $10 Billion Biologics Market - Accesswire
- 2 months ago - Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market - Accesswire
- 3 months ago - Sunshine Biopharma Reports 2025 First Quarter Results, Revenues Up 18% Over Same Period Last Year - Accesswire
- 3 months ago - Sunshine Biopharma Launches Generic Lurasidone for Schizophrenia in the Canadian Sector of the Global $1.2 Billion Market - Accesswire
- 4 months ago - Sunshine Biopharma Launches Everolimus In Canada, an Oncology Drug with an Estimated Global Market of $2.5 Billion - Accesswire
- 4 months ago - Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering - Accesswire
- 4 months ago - Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules - Accesswire
- 4 months ago - Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug - Benzinga